2014
Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages
GUMULEC, Jaromír; Michaela FOJTŮ; Martina RAUDENSKÁ; Markéta SZTALMACHOVÁ; Anna SKOTÁKOVÁ et al.Základní údaje
Originální název
Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages
Autoři
GUMULEC, Jaromír; Michaela FOJTŮ; Martina RAUDENSKÁ ORCID; Markéta SZTALMACHOVÁ; Anna SKOTÁKOVÁ; Jana VLACHOVA; Sylvie SKALICKOVA; Lukáš NEJDL; Pavel KOPEL; Lucia KNOPFOVÁ; Vojtech ADAM; Rene KIZEK; Marie STIBOROVA; Petr BABULA a Michal MASAŘÍK
Vydání
International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2014, 1422-0067
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
10600 1.6 Biological sciences
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14110/14:00078586
Organizační jednotka
Lékařská fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
Apoferritin; Cancer; Cardiotoxicity; Doxorubicin; Encapsulation; Liposome; Modification
Štítky
Příznaky
Recenzováno
Změněno: 24. 4. 2015 13:47, Ing. Mgr. Věra Pospíšilíková
Anotace
V originále
Doxorubicin is an effective chemotherapeutic drug, however, its toxicity is a significant limitation in therapy. Encapsulation of doxorubicin inside liposomes or ferritin cages decreases cardiotoxicity while maintaining anticancer potency. We synthesized novel apoferritin- and liposome-encapsulated forms of doxorubicin (“Apodox” and “lip-8-dox”) and compared its toxicity with doxorubicin and Myocet on prostate cell lines. Three different prostatic cell lines PNT1A, 22Rv1, and LNCaP were chosen. The toxicity of the modified doxorubicin forms was compared to conventional doxorubicin using the MTT assay, real-time cell impedance-based cell growth method (RTCA), and flow cytometry. The efficiency of doxorubicin entrapment was 56% in apoferritin cages and 42% in the liposome carrier. The accuracy of the RTCA system was verified by flow-cytometric analysis of cell viability. The doxorubicin half maximal inhibition concentrations (IC50) were determined as 170.5, 234.0, and 169.0 nM for PNT1A, 22Rv1, and LNCaP, respectively by RTCA. Lip8-dox is less toxic on the non-tumor cell line PNT1A compared to doxorubicin, while still maintaining the toxicity to tumorous cell lines similar to doxorubicin or epirubicin (IC50 = 2076.7 nM for PNT1A vs. 935.3 and 729.0 nM for 22Rv1 and LNCaP). Apodox IC50 was determined as follows: 603.1, 1344.2, and 931.2 nM for PNT1A, 22Rv1, and LNCaP.